AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11 per share in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE